首页> 外文期刊>Thoracic cancer. >Nomogram to predict cause‐specific mortality in extensive‐stage small cell lung cancer: A competing risk analysis
【24h】

Nomogram to predict cause‐specific mortality in extensive‐stage small cell lung cancer: A competing risk analysis

机译:罗维图预测广泛阶段小细胞肺癌中造成造成损害的死亡率:竞争风险分析

获取原文
           

摘要

Small-cell lung cancer (SCLC) is one of the most aggressive types of lung cancer. The prognosis for SCLC patients depends on many factors. The intent of this study was to construct a nomogram model to predict mortality for extensive-stage SCLC. Original data was collected from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute in the United States. A nomogram prognostic model was constructed to predict death probability for extensive-stage SCLC. A total of 16?554 extensive-stage SCLC patients from 2004 to 2014 in the SEER database were included in this study. Gender, race, age, TNM staging (including tumor extent, nodal status, and metastasis), and treatment (surgery, chemotherapy, and radiotherapy) were identified as independent predictors for lung cancer-specific death for extensive-stage SCLC patients. A nomogram model was constructed based on multivariate models for lung cancer related death and other cause related death. Performance of the two models was validated by calibration and discrimination, with C-index values of 0.714 and 0.638, respectively. A prognostic nomogram model was established to predict death probability for extensive-stage SCLC. This validated prognostic model may be beneficial for treatment strategy choice and survival prediction. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译:小细胞肺癌(SCLC)是最具侵略性的肺癌类型之一。 SCLC患者的预后取决于许多因素。本研究的目的是构建一个载体模型,以预测广泛阶段SCLC的死亡率。从美国国家癌症研究所的监测,流行病学和最终结果(SEER)数据库收集原始数据。构建了一个载体预后模型,以预测广泛阶段SCLC的死亡概率。在本研究中,共有16岁?554级,从2004年到2014年的广泛阶段SCLC患者均纳入这项研究。性别,种族,年龄,TNM分期(包括肿瘤程度,节点状态和转移)以及治疗(手术,化疗和放疗)被鉴定为广泛阶段SCLC患者的肺癌特异性死亡的独立预测因子。基于多变量模型构建了一个载体模型,用于肺癌相关死亡和其他原因相关死亡。通过校准和歧视验证了两种模型的性能,C折射率分别为0.714和0.638。建立了预后的载体模型,以预测广泛阶段SCLC的死亡概率。这种验证的预后模型可能有利于治疗策略选择和生存预测。 ? 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号